Launched: first international clinical trial with CAR T cell therapy for patients with aggressive B-cell non-Hodgkin lymphoma (B-Cell NHL) in Europe
The trial has been designed to determine the efficacy and safety of JCAR017, a chimeric antigen receptor (CAR) T cell therapy, in the treatment of
clinically selected adult patients with relapsed or refractory disease
VHIO is the first site in Spain to conduct a trial with this immunotherapy for this particular patient population
Among the 16 selected sites across Europe, VHIO is also the first to have been granted authorization for patient enrolment
Novel chimeric antigen receptor (CAR) T cell therapy is a rapidly emerging immunotherapy-based approach involving the removal of immune cells from a patient and turbocharging them with new proteins that empower them to recognize and hone in on cancer. The cells are then returned to the patient in large numbers to mount an antitumor attack.
The first CAR T-focused multi-center clinical study for patients with a highly aggressive form of type of blood cancer, B-cell non-Hodgkin lymphoma (B-Cell NHL) – the TRANSCEND World trial, has opened at VHIO. Pere Barba, Clinical Investigator and Hematologist of VHIO’s Experimental Hematology Group, headed by Francesc Bosch, is Principal
Article originally posted at